Week of Massive Pharma Deals and Multi‑hundred‑million Financings
What a week so far: $RHHBY $NRIX deal $JNJ buys Firefly $GSK buys $NUVL $PBLS $770m IPO + $100m placement $TRLN going public by reverse merger ($900m cash) $TNGX $600m secondary $IDYA $300m secondary (on the back of Tango) $SMMT $575m secondary (on disappointing #ASCO26 data)
Combo Achieves 92% ORR, 90% 6‑Month PFS
Some context for that 92% ORR / 90% 6mth landmark PFS in pancreatic cancer for the $TNGX vopimetostat + daraxonrasib combo: vopimetostat monorx 25% ORR, ~90% 6mth PFS $RVMD daraxonrasib monorx 32%, 6mth PFS 56% https://t.co/V7RjXlLrZK
NRIX Secures $700M Upfront, Expands Bexo Into Immunology, Neurology,
$NRIX just got $700m up front for bexo from $RHHBY. Deal includes expansion into immunology, neurology & MS
Sarc041 Verzenio Trial Highlights Pfizer, Not Lilly Opportunities
MSKCC's Sarc041 trial of Verzenio being discussed at #Asco26 plenary right now... actually a really interesting study, but more for $PFE $ONC CDK4 inhibitors than for $LLY, I reckon. I covered it here (pawyalled, soz) -> https://t.co/I7ZspUFfBI
Ivonescimab Plus Chemo Yields 71% Response In
Akeso ph2 trial of ivonescimab + chemo in 1L MSS/pMMR colorectal cancer (incl KRASm & w/t). ORR 71% (32/48). Via David Berz #ASCO26 $SMMT https://t.co/i5NW6fpKAu
Pfizer Inks $600M Deal
$PFE #Asco26 splash: $600m u/f deal with $IVBXF to develop 12 cancer projects, incl ADCs & multispecifics (8 from Innovent, 4 from Pfizer). Projects/targets undisclosed though https://t.co/tVAGO73UOD
AbbVie Acquires Imgen’s ADC After Jazz Passes
Remember Decnupaz (pivekimab sunirine, then coded IMGN632) was one of two Immunogen ADCs $JAZZ decided not to opt into c2020. $ABBV later bought $IMGN for Elahere.
ABBV's BLA for Pivekimab Sunirine Remains Pending
$ABBV announced BLA submission for pivekimab sunirine back in Sep 2025, but no news since on whether this was accepted/Pdufa date set.
Chemo-Free Padcev‑Keytruda Shows Promise for Cis‑eligible Patients
$AZN Volga might have matched $MRK $PFE KN-905 in cis-ineligible patients, but here comes chemo-free Padcev + Keytruda in the cis-eligible setting. Via @ApexOnco -> https://t.co/KmwCfgZLBm
ZYME ADC
Catching up with $ZYME pan-RAS inhibitor payload ADCs from #AACR26. Seems the setting for each one is tumours that are RAS-mutated as well as expressing the target antigen (PTK7, Ly6E or Claudin18.2). https://t.co/hljX5soZQi
Serena-6 Shows Unexpected Immature OS Curves
$AZN Serena-6 immature OS curves as revealed at the adcom. Not sure we've seen these before. https://t.co/L9oAQxhrh9
Tomorrow's Dual AZN ODAC: Serena-6 AM, Truqap-281
Reminder that the dual $AZN ODAC takes place tomorrow. Camizestrant Serena-6 trial being debated in the morning, then Truqap Capitello-281 in the afternoon. Youtube link -> https://t.co/RDcvhRqVWR
ONC Secures $20M for Huahi's Hexavalent Trispecific
If you're wondering what $ONC got for its $20 m, here's the #AACR25 detail on Huahi's HH160, a symmetrical hexavalent trispecific anti PD-1 x CTLA-4 x VEGF-A MAb https://t.co/Y0jVjTuMMo
Dispatch Biotherapeutics Launches First Clinical Trial
Remember Car June's new venture, Dispatch Biotherapeutics (raised $216 m since 2022)? Here's its first clinical trial: https://t.co/EIrZHSeHT8
Key Insights Await From Tovecimig Companion-002 Data
$CMPX data from Companion-002 study of tovecimig coming before 8am ET today. What to look out for, via @ByMadeleineA -> https://t.co/6IDCqMyNPE